Physician profile
Peter J Polack
NPI 1821080771
$434.14
in general payments reported to CMS, 2019-2025
9 companies · $289 in 2025
The $289 reported for 2025 was less than what a typical Cornea and External Diseases Specialist provider received nationally (typical 2025 total: $477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.54 · 2023: $78.82 · 2024: $43.56 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $394 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $393.76 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $134.86 | 2024-2025 | Oxervate |
| Rxsight INC | $128.04 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
| Alcon Vision LLC | $67.17 | 2023-2025 | Argos, Clareon |
| Johnson & Johnson Surgical Vision, INC. | $25.83 | 2025 | Tecnis Iol |
| Harrow Eye, LLC | $21.11 | 2024 | Vevye |
| Bausch & Lomb Americas INC. | $17.84 | 2023 | Miebo |
| Rayner Intraocular Lenses Limited | $16.75 | 2023 | Rayone Spheric, Omidria, Rayone Aspheric |
| Omeros Corporation | $16.47 | 2019 | |
| Biotissue Holdings INC. | $6.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Polack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.